MX2022013650A - Imidazopirimidinas como moduladores de il-17. - Google Patents

Imidazopirimidinas como moduladores de il-17.

Info

Publication number
MX2022013650A
MX2022013650A MX2022013650A MX2022013650A MX2022013650A MX 2022013650 A MX2022013650 A MX 2022013650A MX 2022013650 A MX2022013650 A MX 2022013650A MX 2022013650 A MX2022013650 A MX 2022013650A MX 2022013650 A MX2022013650 A MX 2022013650A
Authority
MX
Mexico
Prior art keywords
imidazopyrimidines
modulators
formula
syndrome
disorder
Prior art date
Application number
MX2022013650A
Other languages
English (en)
Spanish (es)
Inventor
Steven Goldberg
Virginia M Tanis
Xiaohua Xue
connor Martin
Timothy B Rhorer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2022013650A publication Critical patent/MX2022013650A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)
MX2022013650A 2020-04-30 2021-04-28 Imidazopirimidinas como moduladores de il-17. MX2022013650A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017679P 2020-04-30 2020-04-30
PCT/IB2021/053517 WO2021220183A1 (en) 2020-04-30 2021-04-28 Imidazopyrimidines as modulators of il-17

Publications (1)

Publication Number Publication Date
MX2022013650A true MX2022013650A (es) 2023-02-01

Family

ID=75769661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013650A MX2022013650A (es) 2020-04-30 2021-04-28 Imidazopirimidinas como moduladores de il-17.

Country Status (11)

Country Link
US (1) US12559496B2 (enExample)
EP (1) EP4143193B1 (enExample)
JP (1) JP7661361B2 (enExample)
KR (1) KR20230018387A (enExample)
CN (1) CN115867348B (enExample)
AU (1) AU2021262588A1 (enExample)
BR (1) BR112022021957A2 (enExample)
CA (1) CA3181793A1 (enExample)
IL (1) IL297734A (enExample)
MX (1) MX2022013650A (enExample)
WO (1) WO2021220183A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
US10152431B2 (en) 2015-03-16 2018-12-11 Honeywell International Inc. System and method for remote set-up and adjustment of peripherals
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
US11472794B2 (en) * 2018-01-15 2022-10-18 UCB Biopharma SRL Fused imidazole derivatives as IL-17 modulators
CN110511213B (zh) 2018-05-22 2021-10-19 成都先导药物开发股份有限公司 一种免疫调节剂
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
EP3820567A1 (en) * 2018-07-12 2021-05-19 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
US20230167497A1 (en) 2020-04-30 2023-06-01 Xiaohua Xue Methods of identifying modulators of the il-17 pathway
MX2022013637A (es) 2020-04-30 2022-11-16 Janssen Pharmaceutica Nv Nuevos compuestos de triazinoindol.
PE20230469A1 (es) 2020-04-30 2023-03-14 Janssen Pharmaceutica Nv Imidazopiridazinas como moduladores de il-17

Also Published As

Publication number Publication date
JP7661361B2 (ja) 2025-04-14
KR20230018387A (ko) 2023-02-07
EP4143193B1 (en) 2026-04-22
CN115867348B (zh) 2025-05-06
CA3181793A1 (en) 2021-11-04
IL297734A (en) 2022-12-01
JP2023523770A (ja) 2023-06-07
AU2021262588A1 (en) 2023-01-19
US20230242537A1 (en) 2023-08-03
WO2021220183A1 (en) 2021-11-04
US12559496B2 (en) 2026-02-24
CN115867348A (zh) 2023-03-28
BR112022021957A2 (pt) 2023-01-17
EP4143193A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
CO2022017072A2 (es) Imidazopiridazinas como moduladores de il-17
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
CO2024003723A2 (es) Compuestos de imidazopiridazina inhibidores de il-17
CO2023015037A2 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
MX2024003721A (es) Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
MX2020008024A (es) Compuestos de indol carboxamida útiles como inhibidores de cinasas.
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
CU20130094A7 (es) Moduladores de la vía del complemento
GT201400131A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2019008378A (es) Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa.
UY39957A (es) Compuestos de imidazopiridazina inhibidores de il-17
BR112014009717A8 (pt) derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson.
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
MX2023013987A (es) Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
UY33557A (es) Inhibidores de oxadiazol de la produccion de leucotrieno
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
UY40657A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
MX2021012544A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.
CL2022002989A1 (es) Imidazopiridazinas como moduladores de il-17.